Poplar buds could hold untapped potential as an ingredient in anti-ageing skin creams, a study has found.
Poplar buds could hold untapped potential as an ingredient in anti-ageing skin creams, a study has found. Poplar trees and other members of the Populus species are thought to possess great potential for therapeutic applications, and Propolis, a substance made from poplar buds by bees, has a long history as an antioxidant. Antioxidants are important in skin ageing as they can be used to support the body’s defences against reactive oxygen species and the inflammatory effects they cause. A study published in the Journal of Agricultural and Food Chemistry has profiled bud extracts to identify the compounds that cause this effect and their effect on skin ageing.1
The phenolic profile of poplar bud extract was analysed by reversed-phase analytical HPLC, and the main compounds were identified by MS and NMR. The main phenolic compounds were then analysed by assays to determine their individual antioxidant properties. Caffeic and p-coumaric acids were identified as the major antioxidant contributors, which, between them, were found to represent half of the total antioxidant activity of the extract.
A customized DNA microarray specifically designed to investigate skin ageing markers allowed the researchers to test the effect of the extract. According to the study, the results “indicate a potential beneficial effect of poplar bud extract on skin ageing as it showed a strong modulation of transcription of genes involved in antioxidant defences, inflammatory response and cell renewal.” The collective properties were suggested to possess antiageing properties, which could be used in cosmetic and nutraceutical formulations.
1. S. Dudonné et al., J. Agric. Food Chem., 59, 4527–4536 (2011).
This story originally appeared in The Column. Click here to view that issue.
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.
Characterization of Product Related Variants in Therapeutic Monoclonal Antibodies
July 16th 2024Navin Rauniyar and Xuemei Han of Tanvex Biopharma USA recently discussed how identifying product-related variants through characterization enables the recognition of impurities that compromise the quality and safety of drugs.